Literature DB >> 27905855

Reply: Promise and Limitations of Relaxin-based Therapies in Chronic Fibrotic Lung Diseases.

Jiangning Tan1, Daniel J Kass1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27905855      PMCID： PMC5148147          DOI： 10.1164/rccm.201607-1464LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  3 in total

1.  Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

Authors:  Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Talmadge E King; Lisa Lancaster; Paul W Noble; Steven A Sahn; Michiel Thomeer; Dominique Valeyre; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2011-09-22       Impact factor: 21.405

2.  Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

Authors:  Dinesh Khanna; Philip J Clements; Daniel E Furst; Joseph H Korn; Michael Ellman; Naomi Rothfield; Fredrick M Wigley; Larry W Moreland; Richard Silver; Youn H Kim; Virginia D Steen; Gary S Firestein; Arthur F Kavanaugh; Michael Weisman; Maureen D Mayes; David Collier; Mary E Csuka; Robert Simms; Peter A Merkel; Thomas A Medsger; Martin E Sanders; Paul Maranian; James R Seibold
Journal:  Arthritis Rheum       Date:  2009-04

3.  Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis. Implications for Relaxin-based Therapies.

Authors:  Jiangning Tan; John R Tedrow; Justin A Dutta; Brenda Juan-Guardela; Mehdi Nouraie; Yanxia Chu; Humberto Trejo Bittar; Kritika Ramani; Partha S Biswas; Kristen L Veraldi; Naftali Kaminski; Yingze Zhang; Daniel J Kass
Journal:  Am J Respir Crit Care Med       Date:  2016-12-01       Impact factor: 21.405
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.